Navigation Links
Oncolytics(R) Biotech Inc. Announces Issuance of 33rd U.S. Patent
Date:10/27/2009

CALGARY, Oct. 27 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) ("Oncolytics") today announced that it has been granted its 33rd U.S. Patent, # 7,608,257, entitled "Sensitization of Chemotherapeutic Agent Resistant Neoplastic Cells With a Virus." The patent claims cover methods of using reovirus in combination with currently approved chemotherapeutic agents to treat patients that are refractory to those chemotherapeutic agents alone.

"This patent supports our expanding clinical program, including our first Phase III study, looking at REOLYSIN(R) in combination with a range of chemotherapeutic agents," said Mary Ann Dillahunty, Vice President of Intellectual Property for Oncolytics. "Many of our studies enroll patients that did not previously respond to chemotherapy, including our Phase III study in patients with platinum refractory head and neck cancers."

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of human trials including a Phase III trial in head and neck cancers using REOLYSIN(R), its proprietary formulation of the human reovirus. For further information about Oncolytics, please visit: www.oncolyticsbiotech.com.

This news release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including among others, the Company's belief as to the importance of the issuance of this patent, the safety and efficacy of the reovirus, the Company's expectations as to the potential applications of the patented technology and other statements relating to anticipated developments in the Company's business and technologies, involve known and unknown risks and uncertainties that could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the efficacy of REOLYSIN as a cancer treatment, the success and timely completion of clinical studies and trials, uncertainties related to the research and development of pharmaceuticals and uncertainties related to the regulatory process. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements, except as required by applicable laws.

SOURCE Oncolytics Biotech Inc.


'/>"/>
SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Oncolytics(R) Biotech Inc. Completes Patient Enrolment in U.S. Phase 2 Sarcoma Study
2. Syngenta Ventures Invests in U.S. Biotech Company Metabolon
3. Champions Biotechnology Expands Collaboration to Test Oncology Therapeutic in Biomerk Tumorgrafts(TM)
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO Investor Forum 2009
5. Pulmo BioTech Inc. Announces Cash Details of its Previously Announced Letter of Intent Intended to Bring its Pulmonary Vascular Diagnostic Product Candidate PulmoBind(TM) to the European Market
6. Monsanto and Huazhong Agricultural University Enter Into Collaboration Focusing on Development of Plant Biotechnology
7. Oncolytics Biotech(R) Inc. Announces Investment in Private Biotechnology Company
8. Epeius Biotechnologies to Partner at BIO Investor Forum
9. Reportlinker Adds Global Top 10 Biotechnology Companies -- Industry, Financial and SWOT Analysis
10. Sosei Announces Deal With UK Biotech Company
11. Media Advisory - Oncolytics Biotech(R) Inc. to Present at BioPartnering Europe
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... 2016  NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company"), a nanomedicine ... , MD, MPH, will present information about the company,s programs at ... New York City . --> ... Room at 5:30PM EST. Registered attendees can request a one on ... . --> New York City ...
(Date:2/8/2016)... , February 8, 2016 ... Genetics" or the "Company"), the ultra-rapid Point-Of-Care (POC) molecular diagnostics ... Mark its Chlamydia trachomatis (CT) test to be launched on ... IVD Directive (98/79/EC), the CT test is now cleared for ... --> The launch of the io® CT test ...
(Date:2/5/2016)... , Feb. 5, 2016 ATCC, the ... poised to assist the medical and life science researchers ... Zika Virus infection.   CDC website . ... --> Zika virus is a single-stranded RNA virus ... the West Nile, Dengue and Chikungunya Viruses. Zika virus ...
(Date:2/5/2016)... 5, 2016 Amarantus BioScience Holdings, ... focused on developing products for Regenerative Medicine, Neurology and ... Disease Designation (RPDD) from the US Food and Drug ... MANF was previously granted orphan drug designation (ODD) by ... Amarantus BioScience Holdings, Inc. (OTCQB: AMBS), ...
Breaking Biology Technology:
(Date:2/1/2016)... -- Today, the first day of American Heart Month, the ... first of its kind workplace health solution that leverages ... first application of Watson to ... Welltok will create a new offering that combines AHA,s ... on Welltok,s health optimization platform. The effort is intended ...
(Date:1/27/2016)... Ohio , Jan. 27, 2016  Rite Track, ... based in West Chester, Ohio ... award winning service staff, based in Austin, ... capacity and ability to provide modifications, installations and technical ... Dovalina , CEO of PLUS, commented, "PLUS has provided ...
(Date:1/22/2016)... 22, 2016 ... of the  "Global Behavioral Biometric Market ... --> http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has announced ... Biometric Market 2016-2020"  report to their ... Markets ( http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has announced the ...
Breaking Biology News(10 mins):